Compare Stocks: TARA, NGNE, PBYI, and ENTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$3.22 -0.6%	$2.89	$0.91 ▼ $4.20	$564.21M	1.48	448,970 shs	103,319 shs
NGNE Neurogene	$25.10 -0.7%	$28.78	$15.93 ▼ $43.66	$523.32M	1.75	346,443 shs	199,762 shs
PBYI Puma Biotechnology	$8.08 -0.7%	$9.82	$4.76 ▼ $11.50	$420.83M	1.4	462,483 shs	397,807 shs
TARA Protara Therapeutics	$2.62 +7.8%	$2.95	$2.09 ▼ $7.82	$149.62M	1.54	910,273 shs	765,032 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-0.31%	+6.23%	+21.80%	+15.71%	+8.00%
NGNE Neurogene	-2.77%	-5.21%	-4.24%	-31.64%	-10.67%
PBYI Puma Biotechnology	-3.10%	-20.35%	-20.89%	-8.54%	+72.09%
TARA Protara Therapeutics	-3.19%	+0.83%	-11.96%	-37.53%	-46.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$3.22 -0.6%	$2.89	$0.91 ▼ $4.20	$564.21M	1.48	448,970 shs	103,319 shs
NGNE Neurogene	$25.10 -0.7%	$28.78	$15.93 ▼ $43.66	$523.32M	1.75	346,443 shs	199,762 shs
PBYI Puma Biotechnology	$8.08 -0.7%	$9.82	$4.76 ▼ $11.50	$420.83M	1.4	462,483 shs	397,807 shs
TARA Protara Therapeutics	$2.62 +7.8%	$2.95	$2.09 ▼ $7.82	$149.62M	1.54	910,273 shs	765,032 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-0.31%	+6.23%	+21.80%	+15.71%	+8.00%
NGNE Neurogene	-2.77%	-5.21%	-4.24%	-31.64%	-10.67%
PBYI Puma Biotechnology	-3.10%	-20.35%	-20.89%	-8.54%	+72.09%
TARA Protara Therapeutics	-3.19%	+0.83%	-11.96%	-37.53%	-46.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	2.83	Moderate Buy	$9.60	198.14% Upside
NGNE Neurogene	3.00	Buy	$79.57	217.02% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-25.74% Downside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	901.91% Upside

Current Analyst Ratings Breakdown

Latest TARA, NGNE, PBYI, and ENTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/10/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
11/10/2026	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$65.00 ➝ $60.00
10/28/2026	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$65.00
10/15/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	NGNE Neurogene	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	TARA Protara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/8/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	NGNE Neurogene	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$60.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$11.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$40K	14,018.27	N/A	N/A	$1.58 per share	2.04
NGNE Neurogene	$930K	558.68	N/A	N/A	$17.14 per share	1.46
PBYI Puma Biotechnology	$228.40M	1.83	$0.83 per share	9.76	$2.84 per share	2.85
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$2.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$11.44M	-$0.39	N/A	N/A	N/A	N/A	-38.55%	-36.15%	N/A
NGNE Neurogene	-$90.35M	-$5.03	N/A	N/A	N/A	N/A	-44.36%	-40.61%	N/A
PBYI Puma Biotechnology	$31.11M	$0.46	17.57	57.71	N/A	10.26%	17.50%	11.83%	N/A
TARA Protara Therapeutics	-$57.44M	-$1.39	N/A	N/A	N/A	N/A	-46.15%	-42.75%	N/A

Latest TARA, NGNE, PBYI, and ENTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	NGNE Neurogene	-$1.36	-$1.05	+$0.31	-$1.05	N/A	N/A
11/6/2026	Q3 2026	ENTX Entera Bio	-$0.0650	-$0.11	-$0.0450	-$0.11	N/A	N/A
11/6/2026	Q3 2026	TARA Protara Therapeutics	-$0.3657	-$0.35	+$0.0157	-$0.35	N/A	N/A
11/5/2026	Q3 2026	PBYI Puma Biotechnology	$0.09	$0.15	+$0.06	$0.11	$57.50 million	$55.06 million
8/11/2026	Q2 2026	NGNE Neurogene	-$1.42	-$1.53	-$0.11	-$1.53	N/A	N/A
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	128.41	8.98
NGNE Neurogene	N/A	19.97	10.64
PBYI Puma Biotechnology	N/A	3.03	2.64
TARA Protara Therapeutics	N/A	9.01	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
NGNE Neurogene	52.37%
PBYI Puma Biotechnology	61.29%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	3.72%
NGNE Neurogene	11.68%
PBYI Puma Biotechnology	22.20%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	21	174.14 million	167.66 million	Optionable
NGNE Neurogene	131	20.70 million	17.67 million	Optionable
PBYI Puma Biotechnology	179	51.70 million	40.16 million	Optionable
TARA Protara Therapeutics	51	61.57 million	56.89 million	Optionable

TARA, NGNE, PBYI, and ENTX Headlines

Recent News About These Companies

HC Wainwright Has Positive Opinion of TARA FY2026 Earnings

November 11 at 7:11 AM | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for TARA Earnings

November 10 at 6:56 AM | marketbeat.com

Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 6, 2026 | marketscreener.comM

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

November 6, 2026 | globenewswire.com

Protara Therapeutics (TARA) Set to Post Quarterly Earnings on Monday

November 2, 2026 | marketbeat.com

Protara Therapeutics, Inc. (TARA) - What Are Analysts Saying About This Stock?

October 18, 2026 | marketbeat.com

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on ...

October 15, 2026 | finance.yahoo.com

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

October 15, 2026 | globenewswire.com

Protara Therapeutics (NASDAQ:TARA) Stock Price Down 5.3% - Here's Why

October 14, 2026 | marketbeat.com

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

August 21, 2026 | tipranks.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, NGNE, PBYI, and ENTX Company Descriptions

Entera Bio NASDAQ:ENTX

$3.22 -0.02 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 0.00 (0.00%)

As of 07:56 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Neurogene NASDAQ:NGNE

$25.10 -0.18 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$25.07 -0.03 (-0.12%)

As of 07:44 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Puma Biotechnology NASDAQ:PBYI

$8.08 -0.06 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$8.09 +0.01 (+0.12%)

As of 07:56 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Protara Therapeutics NASDAQ:TARA

$2.62 +0.19 (+7.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.59 -0.03 (-1.07%)

As of 07:56 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, NGNE, PBYI, and ENTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, NGNE, PBYI, and ENTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, NGNE, PBYI, and ENTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, NGNE, PBYI, and ENTX Company Descriptions

Entera Bio NASDAQ:ENTX

Neurogene NASDAQ:NGNE

Puma Biotechnology NASDAQ:PBYI

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, NGNE, PBYI, and ENTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, NGNE, PBYI, and ENTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, NGNE, PBYI, and ENTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, NGNE, PBYI, and ENTX Company Descriptions

Entera Bio NASDAQ:ENTX

Neurogene NASDAQ:NGNE

Puma Biotechnology NASDAQ:PBYI

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools